Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Shrinking team NBB
FTE fell two years in a row, from 10.3 to 5.4.
Financials
Financial year 2025
BIO.BE from Charleroi, company number BE0861738595, closed financial year 2025 with a result of € -244,508 after tax. For that financial year BIO.BE recorded a gross margin of € 506,347 and equity of € 1.5 million. Compared with financial year 2024, the result moved from € -725,799 to € -244,508. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.
€ 1.5 million
▼ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -244,508
▲ 66 % less loss than in 2024
Profit after tax over the fiscal year.
€ 157,624
▼ 48% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -261,554.
People and assets in 2025
5.4
▼ 3.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 512,297
▼ 38% vs 2024
€ 94,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 11,337
▼ 39% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 509,725
▼ 13% vs 2024
€ 54,514 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 285,154
▲ 114% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 66,621
▼ 43% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,413,434 | € 234,100 | € 442,965 | € 506,347 | ▲ 14% |
| Profit after taxes | € -612,631 | € -966,125 | € -725,799 | € -244,508 | ▲ € 481,291 |
| Equity | € 3,423,178 | € 2,446,639 | € 1,710,426 | € 1,455,504 | ▼ 15% |
| Total debts | € 1,594,571 | € 1,311,772 | € 1,989,853 | € 1,582,852 | ▼ 20% |
| Cash | € 735,918 | € 492,160 | € 300,696 | € 157,624 | ▼ 48% |
| Land & buildings | € 1,088,303 | € 1,017,996 | € 947,398 | € 878,105 | ▼ 7% |
| Retained profit | € 1,674,878 | € 708,754 | € -17,046 | € -261,554 | ▼ € 244,508 |
| Bank debt | € 711,398 | € 649,628 | € 588,557 | € 509,725 | ▼ 13% |
| Balance sheet total | € 5,017,749 | € 3,758,411 | € 3,700,279 | € 3,038,356 | ▼ 18% |
| Employees (FTE) | 21.6 | 10.3 | 8.6 | 5.4 | ▼ 3.2 |
Key figures of BIO.BE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BIO.BE?
What happened at BIO.BE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Tristan GEURTS stepped down as director. NBB
- Coralie DANIEL stepped down as director. NBB
- Jean-François GHIDETTI stepped down as director. NBB
- Bernard WILLEMART stepped down as director. NBB
- Gauthier SAELENS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 244,508. Source: NBB ↗
- Tristan GEURTS became a director. NBB
- Coralie DANIEL became a director. NBB
In short
From € 612,631 loss in 2022 to € 244,508 loss in 2025.
Paid € 16,000 in corporate taxes since 2022.
On average € 93,800 of value added per employee in 2025.
Management
The stake of Institut de Pathologie et de Génétique comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BIO.BEThe shares are held by Institut de Pathologie et de Génétique (100%). It owns 4.4% of ONCODNA itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2028
Bernard WILLEMART
Director
Also active at: BEVERGAM, Service d'Oncologie Radiothérapie Médecine Nucléaire
since 2025 · until 2028
since 2022 · until 2025
since 2022 · until 2025
Gauthier SAELENS
Director
Also active at: INSTITUT DE PATHOLOGIE ET DE GENETIQUE, Association interhospitalière de la Région de Charleroi, Crèches La Roseraie, UNESSA, Haute École Louvain en Hainaut
since 2025 · until 2028
Tristan GEURTS
Director
since 2025 · until 2028
Coralie DANIEL
Director
since 2025 · until 2028
Denis DUFRASNE
Director
since 2022 · until 2025
Michel MAHAUX
Chairman of the board
since 2022 · until 2025
Shareholders
Participations
4.4%
Establishments
Establishment units
Physical locations of this company
Avenue Georges Lemaitre 25
6041 Charleroi
Rue Louis Breguet 1
6041 Charleroi
Active since 20 November 2003
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
DREAMHOST-AS - New Dream Network, LLC, US
Domain
Domain
seqalis.com
Registered
2021-06-28
Registrar
Infomaniak Network SA
Expires
2026-06-28
Website info
Features
Security
Details
- Company number
- 0861.738.595
- VAT number
- BE 0861.738.595
- Registered office
- Avenue Georges Lemaitre 25, 6041 Charleroi
- Names & denominations
- BIO.BE · Seqalis
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 November 2003
- Peppol
- Active · Active since 17 Oct 2025
- Contact
- seqalis.com
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Medische laboratoria
Activiteiten van medische laboratoria
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige technische testen en toetsen